Heterogeneous nuclear ribonucleoprotein A2, or RA33 is a target for autoantibodies in about one third of RA patients, but also in systemic lupus erythematosus (SLE) and mixed connective tissue disease patients with antibodies against DNA and the Sm/RNP complex (60). Here, RNPC3 is linked to systemic lupus erythematosus.